Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indic...

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Associated Therapies: -

Clinical Trials

Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients

Phase 3

Recruiting

Conditions: Supraventricular Tachycardia (SVtach)

Interventions: Drug: Adenosine
Drug: Verapamil Injection

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-13

Lead Sponsor: Rashid Latif Medical College

Target Recruit Count: 210

Registration Number: NCT06717685

Locations: 🇵🇰
Punjab Institute of Cardiology, Lahore, Punjab, Pakistan

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Phase 4

Recruiting

Conditions: Chronic Coronary Syndrome
Coronary Artery Disease
Ischemic Heart Disease

Interventions: Drug: Adenosine

First Posted Date: 2024-08-29

Last Posted Date: 2024-10-31

Lead Sponsor: Region Skane

Target Recruit Count: 180

Registration Number: NCT06578234

Locations: 🇸🇪
Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

Phase 3

Withdrawn

Conditions: Myocardial Ischemia

Interventions: Drug: Adenosine

First Posted Date: 2021-08-20

Last Posted Date: 2024-05-17

Lead Sponsor: Vastra Gotaland Region

Registration Number: NCT05014061

Adrenaline for the Treatment of No-Reflow in Normotensive Patients

Phase 4

Completed

Conditions: No-Reflow Phenomenon
Acute Coronary Syndrome
Normotensive

Interventions: Drug: Adrenaline
Drug: Adenosine

First Posted Date: 2021-01-07

Last Posted Date: 2021-05-21

Lead Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Target Recruit Count: 201

Registration Number: NCT04699110

Locations: 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Phase 4

Recruiting

Conditions: Takotsubo Syndrome

Interventions: Other: Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Drug: Apixaban 5 mg Oral Tablet
Drug: Adenosine
Drug: Dipyridamole 200 mg

First Posted Date: 2020-12-14

Last Posted Date: 2024-12-02

Lead Sponsor: Vastra Gotaland Region

Target Recruit Count: 1000

Registration Number: NCT04666454

Locations: 🇸🇪
Östersund Sjukhus, Östersund, Jämtland Härjedalen, Sweden
🇸🇪
Region Jönköpings Län, Jönköping, Region Jönköping, Sweden
🇸🇪
Norra Älvsborgs länssjukhus, Trollhättan, Västra Götalands Region, Sweden

and more 13 locations

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Early Phase 1

Conditions: MRI Scans

Interventions: Drug: Adenosine
Drug: Regadenoson
Drug: O-15 labeled radioactive water
Device: MRI
Device: PET Imaging

First Posted Date: 2020-10-23

Last Posted Date: 2020-10-23

Lead Sponsor: University of Utah

Target Recruit Count: 100

Registration Number: NCT04600115

Locations: 🇺🇸
university of Utah, Radiology Research, Salt Lake City, Utah, United States

The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19

Phase 2

Withdrawn

Conditions: Acute Respiratory Distress

Interventions: Drug: Adenosine

First Posted Date: 2020-10-19

Last Posted Date: 2024-05-06

Lead Sponsor: University of Florida

Registration Number: NCT04588441

The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.

Not Applicable

Completed

Conditions: Headache, Migraine

Interventions: Drug: Saline
Drug: Adenosine

First Posted Date: 2020-10-08

Last Posted Date: 2022-11-16

Lead Sponsor: Danish Headache Center

Target Recruit Count: 18

Registration Number: NCT04577443

Locations: 🇩🇰
Rigshospitalet-Glostrup, Glostrup, Nordre Ringvej 57, Denmark

A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)

Phase 3

Completed

Conditions: Supra-ventricular Tachycardia

Interventions: Drug: Adenosine

First Posted Date: 2020-05-18

Last Posted Date: 2021-06-25

Lead Sponsor: University of Pretoria

Target Recruit Count: 30

Registration Number: NCT04392362

Locations: 🇿🇦
Steve Biko hospital, Pretoria, Gauteng, South Africa

Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting

Not Applicable

Completed

Conditions: Supraventricular Tachycardia

Interventions: Drug: verapamil
Drug: adenosine

First Posted Date: 2019-12-18

Last Posted Date: 2020-12-02

Lead Sponsor: Ain Shams University

Target Recruit Count: 268

Registration Number: NCT04203368

Locations: 🇪🇬
Ain Shams university, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy